comparemela.com

Latest Breaking News On - Psych congress - Page 1 : comparemela.com

FDA Clears Cingulate to File for Marketing Approval of

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application Advancing Discussions with Commercialization Partners.

United-states
Kansas
Kansas-city
American
Shanej-schaffer
Matt-kreps
Thomas-dalton
Ann-childress
Darrow-associates
Exchange-commission
Nasdaq
Psych-congress-first-annual-poster

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently .

United-states
Kansas-city
Kansas
American
Shanej-schaffer
Matt-kreps
Thomas-dalton
Ann-childress
Drug-administration
Behavior-medicine-inc
Platform-technology
Securities-exchange

Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"

Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Americans
Derek-maetzold
Steve-johansson
Castle-bioscience
Castle-biosciences
Linkedin
Overall-mental-health-solution
Technology-solution
Mental-health-america
Facebook

Late Breaking News From APSARD 2024 Conference

Check out these APSARD 2024 updates from Greg Mattingly, MD, president of the American Professional Society for ADHD and Related Disorders.

Netherlands
United-states
Israel
Australia
American
America
Australian
Jeff-newcorn
Ann-childress
Joseph-biederman
David-goodman
Greg-mattingly

Medication Pipeline: Schizophrenia and PTSD

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

Exeter-hospital
New-hampshire
United-states
Micronesia
Massachusetts
Palau
Emil-kraepelin
Clin-neurosci
Karuna-therapeutics-inc
Minerva-neurosciences-inc
Wunderlichg-development
Public-benefit-corp

vimarsana © 2020. All Rights Reserved.